A database of FDA approved therapeutic peptides and proteins
Details of Th1219 which contains 1 entries. |
| Entry 1 | |
| (1) Primary information | |
|---|---|
| ID | 1829 |
| ThPP ID | Th1219 |
| Therapeutic Peptide/Protein Name | Anti-thymocyte Globulin (Rabbit) |
| Sequence | NA view full sequnce in fasta |
| Functional Classification | IIIb |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting Point (℃) | 61 °C (FA |
| Half Life | 2-3 days, may increase after multiple doses administration |
| Description | Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin is via selective depletion of T-cells. |
| Indication/Disease | For prevention of renal transplant rejection |
| Pharmacodynamics | Antithymocyte Globulin (ATG) is a concentrated anti-human T-lymphocyte immunoglobulin preparation derived from rabbits after immunization with a T-lympoblast cell line. ATG is an immunosuppressive product for the prevention and treatment of acute rejection following organ transplantation. ATG reduces the host immune response against tissue transplants or organ allografts. |
| Mechanism of Action | Binds to multiple, T-cell specific antigens leading to T-lymphocyte cell death via complement mediated cytotoxicity or apoptosis. |
| Toxicity | Not known whether ATG (rabbit) distributes into human milk; however, other immunoglobulins are distributed into human milk. |
| Metabolism | Most likely removed by opsonization via the reticuloendothelial system when bound to T lymphocytes, or by human antimurine antibody production. |
| Absorption | T-cell depletion usually observed within 1 day after initiating therapy. Average 21.5 and 87 mcg/mL 4–8 hours post-infusion after first and last IV doses, respectively, when given for 7–11 days. |
| Volume of Distribution | NA |
| Clearance | NA |
| Categories | Antibody |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | The risk or severity of adverse effects can be increased with combination of drugs like BCG, Denosumab, Fingolimod, G17DT, GI-5005, INGN 201, INGN 225, Leflunomide, Natalizumab, Pimecrolimus. |
| Target | T-cell surface glycoprotein CD1a, Major histocompatibility complex class I-related gene protein, Integrin alpha-L, T-lymphocyte activation antigen CD86, Low affinity immunoglobulin gamma Fc region receptor II-b, T-cell surface glycoprotein CD4, Integrin beta-1, Integrin alpha-V, Integrin beta-3 |
| Information of corresponding available drug in the market | |
| Brand Name | ATG-Fresenius |
| Company | Genzyme Inc. |
| Brand Discription | ATG-Fresenius S 20 mg/ml concentrate for solution for infusion. |
| Prescribed for | ATG-Freseniusis usually used in combination with other immunosuppressive drugs(corticosteroids,azathioprine,cyclosporineA,etc.) to suppress the immune system and thus preventing rejection following organ transplantation. |
| Chemical Name | NA |
| Formulation | One ml of the concentrate contains 20 mg anti-human T-lymphocyte immunoglobulin from rabbits |
| Physcial Appearance | Concentrate for solution for infusion. |
| Route of Administration | Intravenous |
| Recommended Dosage | One ml of the concentrate contains 20 mg anti-human T-ddiThe recommended dose range is 2 to 5 mg/kg/d ATG - Fresenius S. The most common doses are in the range of 3 to 4 mg/kg/ dlymphocyte immunoglobulin from rabbits |
| Contraindication | Hypersensitivity to the active substance or to any of the excipients |
| Side Effects | bladder pain,chest pain,chills |
| Useful Link | http://www.pharmaline.co.il/images/newsletterregistration/neopharm/2012/11052012/atgdr.pdf |
| PubMed ID | 24907357, 25672649, 12783210, 25243624 |
| 3-D Structure | Th1219 (View) or (Download) |